News

December 09, 2008

Celator Pharmaceuticals Presents Phase 1 Results with CPX-351

October 23, 2008

Arginetix, Inc. Completes $2.3 Million Initial Financing and Technology License

October 8, 2008

FDA Clears Neurostar® TMS Therapy for the Treatment of Depression

October 6, 2008

Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron® in Hepatitis C

October 6, 2008

Biolex Therapeutics Enters Into Agreement to Acquire Full Locteron® Commercial Rights

October 1, 2008

Tranzyme Pharma Announces Positive Phase IIb Results with Its Ghrelin Agonist, TZP-101, for Postoperative Ileus (POI)

August 1, 2008

EKR Therapeutics Receives Approval for Ready-to-Use Intravenous Bags of Cardene® I.V.

June 17, 2008

Tranzyme Pharma’s Ghrelin Agonist TZP-102 Demonstrates Safety and High Oral Bioavailability in the Successful Completion of a Phase I Trial

June 13, 2008

Transave Announces Positive Phase II Results for Once-daily Arikace™ in the Treatment of Cystic Fibrosis Patients who ave Pseudomonas Lung Infections

June 3, 2008

Protez Pharmaceuticals to be Acquired by Novartis for up to $400 million in cash

April 15, 2008

BioWorld Today: Diasome Pharmaceuticals Series B Financing Announcement

March 31, 2008

Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing

March 10, 2008

Philadelphia Inquirer: Philly VCs back Jersey drug seller EKR

March 10, 2008

EKR Therapeutics Raises Over $145 Million in Support of Growth

February 12, 2008

Nitric BioTherapeutics Hires Joel Lippman, M.D. as GM of Its Antimicrobial Business

January 29, 2008

Tranzyme Pharma Receives IND Clearance for Its Oral Ghrelin Agonist, TZP-102, for the Treatment of Gastroparesis